1. Home
  2. ELTX vs WEA Comparison

ELTX vs WEA Comparison

Compare ELTX & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELTX
  • WEA
  • Stock Information
  • Founded
  • ELTX 2011
  • WEA 2002
  • Country
  • ELTX United States
  • WEA United States
  • Employees
  • ELTX N/A
  • WEA N/A
  • Industry
  • ELTX Biotechnology: Pharmaceutical Preparations
  • WEA Trusts Except Educational Religious and Charitable
  • Sector
  • ELTX Health Care
  • WEA Finance
  • Exchange
  • ELTX Nasdaq
  • WEA Nasdaq
  • Market Cap
  • ELTX 121.7M
  • WEA 129.0M
  • IPO Year
  • ELTX N/A
  • WEA N/A
  • Fundamental
  • Price
  • ELTX $5.40
  • WEA $10.61
  • Analyst Decision
  • ELTX Strong Buy
  • WEA
  • Analyst Count
  • ELTX 2
  • WEA 0
  • Target Price
  • ELTX $9.50
  • WEA N/A
  • AVG Volume (30 Days)
  • ELTX 35.2K
  • WEA 46.1K
  • Earning Date
  • ELTX 05-19-2025
  • WEA 01-01-0001
  • Dividend Yield
  • ELTX N/A
  • WEA 7.87%
  • EPS Growth
  • ELTX N/A
  • WEA N/A
  • EPS
  • ELTX N/A
  • WEA N/A
  • Revenue
  • ELTX N/A
  • WEA N/A
  • Revenue This Year
  • ELTX N/A
  • WEA N/A
  • Revenue Next Year
  • ELTX N/A
  • WEA N/A
  • P/E Ratio
  • ELTX N/A
  • WEA N/A
  • Revenue Growth
  • ELTX N/A
  • WEA N/A
  • 52 Week Low
  • ELTX $3.34
  • WEA $9.60
  • 52 Week High
  • ELTX $11.45
  • WEA $11.29
  • Technical
  • Relative Strength Index (RSI)
  • ELTX 48.43
  • WEA 44.92
  • Support Level
  • ELTX $4.85
  • WEA $10.56
  • Resistance Level
  • ELTX $5.94
  • WEA $10.72
  • Average True Range (ATR)
  • ELTX 0.50
  • WEA 0.16
  • MACD
  • ELTX 0.14
  • WEA -0.02
  • Stochastic Oscillator
  • ELTX 56.45
  • WEA 15.22

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

About WEA Western Asset Bond Fund Share of Beneficial Interest

Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.

Share on Social Networks: